Table 2.
Comparison of sociodemographic and clinicopathologic characteristics of patients receiving preoperative chemotherapy and gastrectomy for gastric adenocarcinoma who did and did not receive postoperative chemotherapy after propensity-matching
| Characteristic | No postoperative chemotherapy (n = 1091) n (%) |
Postoperative chemotherapy (n = 1091) n (%) |
p value |
|---|---|---|---|
| Median age: years (IQR) | 61 (44–78) | 61 (44–78) | 0.668 |
| Sex | 0.685 | ||
| Male | 718 (65.8) | 709 (65.0) | |
| Female | 373 (34.2) | 382 (35.0) | |
| Race | 0.823 | ||
| White | 803 (73.6) | 813 (74.5) | |
| Black | 150 (13.7) | 149 (13.7) | |
| Asian | 112 (10.3) | 100 (9.2) | |
| Other | 26 (2.4) | 29 (2.7) | |
| Year of diagnosis | 0.827 | ||
| 2006–2009 | 209 (19.2) | 205 (18.8) | |
| 2010–2014 | 882 (80.8) | 886 (81.2) | |
| Insurance status | 0.674 | ||
| No insurance | 48 (4.4) | 40 (3.7) | |
| Private insurance | 546 (50.0) | 570 (52.2) | |
| Medicare | 382 (35.0) | 372 (34.1) | |
| Medicaid/other government aid | 115 (10.5) | 109 (10.0) | |
| Charlson-Deyo Comorbidity score | 0.747 | ||
| 0 | 817 (74.9) | 832 (76.3) | |
| 1 | 232 (21.3) | 218 (20.0) | |
| > 1 | 42 (3.8) | 41 (3.8) | |
| Surgical procedure performed | 0.888 | ||
| Partial gastrectomy (excluding wedge) | 386 (35.4) | 392 (35.9) | |
| Total gastrectomy | 556 (51.0) | 545 (50.0) | |
| Extended gastrectomy | 149 (13.7) | 154 (14.1) | |
| Primary tumor site | 0.752 | ||
| Proximal | 402 (36.8) | 379 (34.7) | |
| Middle | 250 (22.9) | 264 (24.2) | |
| Distal | 263 (24.1) | 265 (24.3) | |
| Unspecified | 176 (16.1) | 183 (16.8) | |
| Facility type | 0.618 | ||
| Academic | 650 (59.6) | 642 (58.8) | |
| Other | 391 (35.8) | 389 (35.7) | |
| Unknown | 50 (4.6) | 60 (5.5) | |
| AJCC tumor classification | 0.939 | ||
| T1 | 94 (8.6) | 93 (8.5) | |
| T2 | 134 (12.3) | 137 (12.6) | |
| T3 | 596 (54.6) | 583 (53.4) | |
| T4 | 267 (24.5) | 278 (25.5) | |
| AJCC nodal classification | 0.821 | ||
| NX | 20 (1.8) | 27 (2.5) | |
| N0 | 470 (43.1) | 455 (41.7) | |
| N1 | 211 (19.3) | 222 (20.3) | |
| N2 | 209 (19.2) | 197 (18.1) | |
| N3a | 126 (11.5) | 130 (11.9) | |
| N3b | 55 (5.0) | 60 (5.5) | |
| AJCC stage (ypTNM)a | 0.855 | ||
| I | 159 (14.9) | 159 (15.1) | |
| II | 487 (45.7) | 470 (44.5) | |
| III | 420 (39.4) | 427 (40.4) | |
| Lymph nodes examined | 0.851 | ||
| < 15 | 324 (29.7) | 320 (29.3) | |
| ≥ 15 | 767 (70.3) | 771 (70.7) | |
| Grade | 0.873 | ||
| Well-/moderately differentiated | 253 (23.2) | 246 (22.5) | |
| Poorly differentiated/undifferentiated | 750 (68.7) | 761 (69.8) | |
| Undetermined/unknown | 88 (8.1) | 84 (7.7) | |
| Lymphovascular invasion | 0.798 | ||
| Not present | 387 (35.5) | 395 (36.2) | |
| Present | 309 (28.3) | 295 (27.0) | |
| Unknown | 395 (36.2) | 401 (36.8) | |
| Margin status | 0.550 | ||
| R0 | 1021 (93.6) | 1014 (92.9) | |
| R1 | 70 (6.4) | 77 (7.1) |
IQR, interquartile range; AJCC, American Joint Committee on Cancer
aPatients labeled as T4 with no subclassification or NX were excluded